AZD2516 + Placebo
Phase 1CompletedDevelopment Stage
Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.
Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years., Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80
Jun 1, 2010 → Jul 1, 2010
About AZD2516 + Placebo
AZD2516 + Placebo is a phase 1 stage product being developed by AstraZeneca for Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.. The current trial status is completed. This product is registered under clinical trial identifier NCT01148095. Target conditions include Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years., Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80.
Hype Score Breakdown
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01148095 | Phase 1 | Completed |
| NCT00972049 | Phase 1 | Completed |
| NCT00754715 | Phase 1 | Completed |
Competing Products
20 competing products in Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2409021 | Eli Lilly | Phase 1 | 33 |
| Ixekizumab | Celltrion | Phase 1 | 33 |
| YH35995 + Placebo | Yuhan | Phase 1 | 33 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| ASP8731 + ASP8731 Matching Placebo | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| Rosuvastatin + BPN14770 | Shionogi | Phase 1 | 33 |
| S-892216-LAI + Placebo | Shionogi | Phase 1 | 33 |
| S-740792 Suspension + Midazolam + Placebo + S-740792 Tablet | Shionogi | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| E2007 | Eisai | Phase 3 | 77 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| E7386 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Pre-clinical | 23 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| Perampanel + Perampanel | Eisai | Phase 1 | 33 |
| H3B-6527 | Eisai | Phase 1 | 33 |
| E3112 | Eisai | Phase 1 | 33 |